What model do I use and why?

What are global experts saying about the future of population health? In the first of three special episodes Shaping the future goes on the road! Phil travels to Chicago to the Mount Hood Diabetes Challenge and talks to Professor Tony Blakely from the University of Melbourne. Producer note: The interviews for this episode were recorded […]

New episode out now. No data. Huge decisions. Traditional models struggle with rare diseases, so how do you prove value when data barely exists? Phil and Marc are joined by Jennifer Lee. Listen wherever you get your podcasts.

New episode out now. AI won’t save healthcare. But it might reshape it. Phil is joined by Tom Padgett, Cerys Mitchell and Josh Cronin-Lampe to discuss the use of AI in healthcare. AI promises transformation but what can it really deliver, and where does it fall short? Listen wherever you get your podcasts.

Crisis or just bad headlines? In this special guest episode, Marc sits down with Cerys Mitchell, Tom Padgett and Geraint Roberts. Is the UK healthcare system declining, or just under pressure? We separate perception from reality.

AI was everywhere at ISPOR 2026, but the conversation has matured well past the hype. In this final episode of the series, Phil and Marc look at where agentic AI and large language models are genuinely changing HEOR practice — from AI-assisted systematic literature reviews to frameworks for evaluating AI use in submissions. They also […]

What does “value” mean in healthcare in 2026? This episode tracks a theme running through ISPOR sessions all week: the limitations of the QALY as the dominant currency of cost-effectiveness, and the methods, distributional cost-effectiveness analysis among them, being developed to better capture equity. Phil, Marc and guest Hamzah Aideed also bring it home to […]

Real-world evidence has moved from a supplementary nice-to-have to a central plank of HTA submissions — but with that shift comes a harder set of questions. In this episode, Phil, Marc and Hamzah Aideed look at what ISPOR 2026 revealed about the state of RWE: the push to use unconventional data sources, including patient-reported and […]

In this opening episode of our ISPOR 2026 debrief series, Phil McEwan and Hamzah Aideed unpack the policy story dominating Philadelphia this year: how the US is moving to reshape drug pricing, and what that means for the rest of the world. From the Most Favoured Nation pricing strategy to ongoing Medicare negotiations under the […]

A model is only useful if people understand it. So how do you turn complex outputs into real-world decisions?

From simple equations to complex simulations how to choose the tools that shape healthcare policy.